Literature DB >> 33156463

COVID-19-Associated Histoplasmosis in an AIDS Patient.

Rossana Patricia Basso1,2, Vanice Rodrigues Poester1, Jéssica Louise Benelli1, David A Stevens3,4, Heruza Einsfeld Zogbi1,2, Izadora Clezar da S Vasconcellos5, Alessandro Comarú Pasqualotto5, Melissa Orzechowski Xavier6,7,8.   

Abstract

Most reports associating fungal infections with COVID-19 have been cases of invasive aspergillosis. Here, we report a case of severe histoplasmosis and COVID-19 infections in an HIV patient in Rio Grande, Southern Brazil. Histoplasmosis must be included as a diagnostic possibility in opportunistic fungal co-infections in COVID-19 patients with AIDS, mainly in endemic areas.

Entities:  

Keywords:  AIDS; COVID-19; Histoplasma capsulatum; Mycoses; SARS-CoV-2

Mesh:

Substances:

Year:  2020        PMID: 33156463      PMCID: PMC7644795          DOI: 10.1007/s11046-020-00505-1

Source DB:  PubMed          Journal:  Mycopathologia        ISSN: 0301-486X            Impact factor:   2.574


Introduction

The COVID-19 pandemia has so far affected more than 39 million people all over the world, causing more than one million deaths [1]. Several co-infections are known to affect patients with severe COVID-19, which may be challenging particularly in terms of diagnosis and treatment, potentially affecting patient outcomes [2, 3]. The frequency of COVID-19 in AIDS is not higher than the frequency of COVID-19 in the general population, even though the true role of the SARS-CoV-2 virus in HIV patients remains to be fully elucidated [4, 5]. Even more challenging is the diagnosis of fungal infections in patients with COVID-19, with most of the infections being associated with Candida and Aspergillus species [2, 3]. Indeed, coronavirus-associated pulmonary aspergillosis (CAPA) is a concern in COVID-19 patients, occurring in 20–35% of patients with severe acute respiratory syndrome (SARS), mainly in those requiring admission to the intensive care unit (ICU) and mechanical ventilation [2, 6, 7]. Similarly, candidemia occurs in 2.5–6.9% of COVID-19 patients in the ICU, mainly catheter-related infections and often with unfavorable outcomes [3, 8]. In addition, individual reports of Pneumocystis spp. co-infection in COVID-19 patients are being described [9, 10]. On the other hand, histoplasmosis, an emergent systemic fungal infection in HIV patients in Brazil and other Latin American countries [11, 12], has not yet been described in the context of COVID-19. Here, we report a case of COVID-19 in a patient who was subsequently diagnosed with histoplasmosis.

Case Report

A 43-year-old homeless woman from Rio Grande (South of Brazil) with a 21-year history of HIV infection and drug abuse (crack cocaine) was poorly adherent to active antiretroviral treatment (ART). She had two hospitalizations (2012 and 2017) due to neurotoxoplasmosis. Her most recent CD4 count was low, at 113 cells/mm3, and her HIV viral load was 38,503 RNA copies/ml (4.58 log). On July 9, 2020, she was admitted to the hospital due to disorientation, cough, dyspnea, and low-grade fever. Chest computed tomography (CT) showed multiple centrilobular nodules, with ground-glass attenuation in both lungs, diffuse thickening of bronchial walls, and lymph node enlargement in the mediastinal and cervical chains and the retroperitoneal upper abdomen (measuring up to 2.7 cm on its smallest axis). Abdominal CT showed hepatosplenomegaly. Sputum microscopy stained by Gomori–Grocott showed abundant small oval blastoconidia suggestive of Histoplasma capsulatum (Fig. 1), but sputum culture was negative for both Mycobacterium tuberculosis and fungi. Histoplasma and Aspergillus precipitins tests were negative, as well as PCR test for SARS-CoV-2 virus (kit Bio-Manguinhos/FIOCRUZ, Lot 66/2020). She was put on empirical therapy for neurotoxoplasmosis and discharged from the hospital with antiretroviral therapy (tenofovir/lamivudine and atazanavir/ritonavir).
Fig. 1

Sputum microscopy showing abundant small oval blastoconidia (arrow) without pseudo-hyphae (Gomori-Grocott stain)

Sputum microscopy showing abundant small oval blastoconidia (arrow) without pseudo-hyphae (Gomori-Grocott stain) On July 17, 2020, the patient returned with worsening dyspnea and oxygen saturation of 83%. Dexamethasone (6 mg, intravenous), ceftriaxone, azithromycin, and oxygen supplementation by nasal catheter were prescribed. At this time, she was diagnosed with COVID-19 by a positive PCR test (kit Bio-Manguinhos/FIOCRUZ, Lot 66/2020). Blood testing revealed anemia (hemoglobin of 9.6 g/dl), mild leukocytosis (10,190/mm3), thrombocytopenia (130,000/mm3), and elevated C-reactive protein (140 mg/l) and d-dimer (2 µg/ml). Chest CT showed several sparse micro-nodules in the lungs, with a nodule in the posterior segment of the upper lobe of the right lung (measuring 4 mm) and intraparenchymal nodule (7 mm), lymph node enlargement in the mediastinal and cervical region (up to 2.5 cm). Abdominal CT showed confluent lymph node enlargements in the retroperitoneal region (biggest measuring 3 × 1.7 cm) and hepatosplenomegaly (Fig. 2). She was discharged from the hospital, but since the urine sample result became positive for H. capsulatum antigen (galactomannan) in immunoenzymatic assay (catalog number HGM201; IMMY®, Immuno-Mycologics, Oklahoma, USA; index of > 2) she was asked to return to the hospital again. She refused hospitalization, and itraconazole PO was commenced at 200 mg twice daily.
Fig. 2

Computed tomography of the chest (a) and abdomen (b) of July 17, 2020. c, d Images show follow-up computed tomography performed on September 14, 2020

Computed tomography of the chest (a) and abdomen (b) of July 17, 2020. c, d Images show follow-up computed tomography performed on September 14, 2020 Patient was last seen on September 14, 2020. Her HIV viral load was 400 copies/ml (2.6 log), and CD4 count was 593 cells/mm3. Follow-up abdominal CT showed persistence of hepatosplenomegaly and abdominal lymph node enlargement, while chest CT revealed an increase in the number of lymph nodes affected compared to the previous examination from July (Fig. 2). Anemia persisted and an increase in inflammatory markers was detected, suggesting active disease. Her medical team is doing their best in an attempt to readmit the patient to receive IV antifungal therapy.

Discussion

Here we present the first Brazilian report of disseminated histoplasmosis associated with COVID-19 in an HIV-infected patient. Despite the co-infections with aggressive pathogens, our patient did not develop severe lung deterioration, nor was intensive care and mechanical ventilation necessary. The favorable outcome of COVID-19 in this patient might be related to her low CD4 cell count, which might have prevented the occurrence of a cytokine storm, as described in patients with severe COVID-19, as well as in those initiating antiretroviral therapy with immune reconstitution syndrome [5]. Disseminated histoplasmosis (DH) is one of the most common opportunistic diseases in HIV/AIDS patients and presents many diagnostic challenges. The symptoms are nonspecific and overlap with other opportunistic diseases, and there is a variation in the sensitivity of diagnostic methods (30–95%) [13, 14]. Our patient was investigated for DH with the use of the three diagnostic methods available locally, i.e., microscopy, culture, and agar gel immunodiffusion test. Despite being highly suggestive of histoplasmosis, findings at sputum microscopy were not considered definitive and the diagnosis was only made by H. capsulatum antigen testing, performed in other institution. Even though antigen testing has a high sensitivity in diagnosing DH (95%) [14], the method is at the moment available for research purposes only in Brazil. This led to a delay in the diagnosis of DH and consequently in the initiation of treatment, which can affect a patient’s outcome. Efforts to increase the availability of the test for urinary antigen detection in DH diagnosis are urgent, especially in regions with a high HIV prevalence [11, 15]. The patient in this report comes from Rio Grande, the municipality with the highest prevalence of HIV/AIDS among Brazilian cities with more than 100,000 inhabitants [16]. Co-infections in COVID-19 and especially in the SARS-CoV-2/HIV patients should be widely investigated since correct treatment would contribute to a favorable outcome [4, 5]. Moreover, fungal infections play an important role as opportunistic infections in HIV or COVID-19 patients, and possible co-infections in both populations should be considered, and appropriate screening tests performed [2, 3, 9].
  13 in total

1.  Essential in vitro diagnostics for advanced HIV and serious fungal diseases: international experts' consensus recommendations.

Authors:  Felix Bongomin; Nelesh P Govender; Arunaloke Chakrabarti; Florence Robert-Gangneux; David R Boulware; Afia Zafar; Rita O Oladele; Malcolm D Richardson; Jean-Pierre Gangneux; Ana Alastruey-Izquierdo; Joel Bazira; Tom H Boyles; Jahit Sarcarlal; Mathieu Nacher; Taminori Obayashi; William Worodria; Alessandro C Pasqualotto; David B Meya; Ben Cheng; Charlotte Sriruttan; Conrad Muzoora; Andrew Kambugu; Juan Luis Rodriguez Tudela; Alexander Jordan; Tom M Chiller; David W Denning
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-09       Impact factor: 3.267

2.  COVID-19 in people with HIV.

Authors:  Zhe Xu; Chao Zhang; Fu-Sheng Wang
Journal:  Lancet HIV       Date:  2020-05-28       Impact factor: 12.767

3.  Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort.

Authors:  Pilar Vizcarra; María J Pérez-Elías; Carmen Quereda; Ana Moreno; María J Vivancos; Fernando Dronda; José L Casado
Journal:  Lancet HIV       Date:  2020-05-28       Impact factor: 12.767

4.  Histoplasmosis, An Underdiagnosed Disease Affecting People Living With HIV/AIDS in Brazil: Results of a Multicenter Prospective Cohort Study Using Both Classical Mycology Tests and Histoplasma Urine Antigen Detection.

Authors:  Diego R Falci; Alexandre A Monteiro; Cassia Ferreira Braz Caurio; Tulio C O Magalhães; Melissa O Xavier; Rossana P Basso; Marineide Melo; Alexandre V Schwarzbold; Paulo Roberto Abrão Ferreira; Jose Ernesto Vidal; João Paulo Marochi; Cassia Silva de Miranda Godoy; Renata de Bastos Ascenco Soares; Aurea Paste; Monica B Bay; Vera Lucia Pereira-Chiccola; Lisandra Serra Damasceno; Terezinha do Menino Jesus Silva Leitão; Alessandro C Pasqualotto
Journal:  Open Forum Infect Dis       Date:  2019-04-13       Impact factor: 3.835

5.  Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an increased risk for candidemia?

Authors:  Spinello Antinori; Cecilia Bonazzetti; Guido Gubertini; Amedeo Capetti; Cristina Pagani; Valentina Morena; Sara Rimoldi; Laura Galimberti; Piercarlo Sarzi-Puttini; Anna Lisa Ridolfo
Journal:  Autoimmun Rev       Date:  2020-05-05       Impact factor: 9.754

6.  COVID-19-associated Pulmonary Aspergillosis.

Authors:  Andreas L E van Arkel; Tom A Rijpstra; Huub N A Belderbos; Peter van Wijngaarden; Paul E Verweij; Robbert G Bentvelsen
Journal:  Am J Respir Crit Care Med       Date:  2020-07-01       Impact factor: 21.405

7.  A Case of COVID-19 and Pneumocystis jirovecii Coinfection.

Authors:  Aravind A Menon; David D Berg; Elliot J Brea; Aaron J Deutsch; Khameer K Kidia; Emilia G Thurber; Sylvie B Polsky; Tiffany Yeh; Jonathan A Duskin; Alison M Holliday; Elizabeth B Gay; Laura E Fredenburgh
Journal:  Am J Respir Crit Care Med       Date:  2020-07-01       Impact factor: 21.405

8.  COVID-19-associated invasive pulmonary aspergillosis.

Authors:  Lynn Rutsaert; Nicky Steinfort; Tine Van Hunsel; Peter Bomans; Reinout Naesens; Helena Mertes; Hilde Dits; Niels Van Regenmortel
Journal:  Ann Intensive Care       Date:  2020-06-01       Impact factor: 6.925

9.  Epidemiology of Invasive Pulmonary Aspergillosis Among Intubated Patients With COVID-19: A Prospective Study.

Authors:  Michele Bartoletti; Renato Pascale; Monica Cricca; Matteo Rinaldi; Angelo Maccaro; Linda Bussini; Giacomo Fornaro; Tommaso Tonetti; Giacinto Pizzilli; Eugenia Francalanci; Lorenzo Giuntoli; Arianna Rubin; Alessandra Moroni; Simone Ambretti; Filippo Trapani; Oana Vatamanu; Vito Marco Ranieri; Andrea Castelli; Massimo Baiocchi; Russell Lewis; Maddalena Giannella; Pierluigi Viale
Journal:  Clin Infect Dis       Date:  2021-12-06       Impact factor: 9.079

10.  Concurrent COVID-19 and Pneumocystis jirovecii pneumonia in a severely immunocompromised 25-year-old patient.

Authors:  Pavan Bhat; Mandee Noval; James B Doub; Emily Heil
Journal:  Int J Infect Dis       Date:  2020-08-05       Impact factor: 3.623

View more
  18 in total

Review 1.  COVID-19-associated opportunistic infections: a snapshot on the current reports.

Authors:  Amir Abdoli; Shahab Falahi; Azra Kenarkoohi
Journal:  Clin Exp Med       Date:  2021-08-23       Impact factor: 5.057

2.  Human Immunodeficiency Virus and Severe Acute Respiratory Syndrome Coronavirus 2 Coinfection: A Systematic Review of the Literature and Challenges.

Authors:  Raj H Patel; Arpan Acharya; Hitendra S Chand; Mahesh Mohan; Siddappa N Byrareddy
Journal:  AIDS Res Hum Retroviruses       Date:  2021-03-23       Impact factor: 2.205

3.  Acute Pulmonary Histoplasmosis Following COVID-19: Novel Laboratorial Methods Aiding Diagnosis.

Authors:  Priscila Marques de Macedo; Andrea D'Ávila Freitas; Thiago Prudente Bártholo; Andrea Reis Bernardes-Engemann; Marcos de Abreu Almeida; Fernando Almeida-Silva; Rosely Maria Zancopé-Oliveira; Rodrigo Almeida-Paes
Journal:  J Fungi (Basel)       Date:  2021-04-28

4.  The microbiome of bat guano: for what is this knowledge important?

Authors:  Ivica Dimkić; Djordje Fira; Tamara Janakiev; Jovana Kabić; Miloš Stupar; Marija Nenadić; Nikola Unković; Milica Ljaljević Grbić
Journal:  Appl Microbiol Biotechnol       Date:  2021-01-29       Impact factor: 4.813

5.  COVID-19 and Fatal Sepsis Caused by Hypervirulent Klebsiella pneumoniae, Japan, 2020.

Authors:  Tomohiro Hosoda; Sohei Harada; Koh Okamoto; Sumire Ishino; Makoto Kaneko; Masahiro Suzuki; Ryota Ito; Miyuki Mizoguchi
Journal:  Emerg Infect Dis       Date:  2020-12-15       Impact factor: 6.883

Review 6.  HIV and COVID-19 in Latin America and the Caribbean.

Authors:  Patricia J Garcia; Diego M Cabrera; Paloma M Cárcamo; Monica M Diaz
Journal:  Curr HIV/AIDS Rep       Date:  2022-01-29       Impact factor: 5.495

Review 7.  Fungal Colonization and Infections-Interactions with Other Human Diseases.

Authors:  Shanmuga S Mahalingam; Sangeetha Jayaraman; Pushpa Pandiyan
Journal:  Pathogens       Date:  2022-02-06

Review 8.  Fungal Infections Other Than Invasive Aspergillosis in COVID-19 Patients.

Authors:  Kerri Basile; Catriona Halliday; Jen Kok; Sharon C-A Chen
Journal:  J Fungi (Basel)       Date:  2022-01-06

9.  Disseminated histoplasmosis in an immunocompetent patient with COVID-19 pneumonia.

Authors:  Genesis Perez Del Nogal; Andres Mata; Prince Ernest; Ivania Salinas
Journal:  BMJ Case Rep       Date:  2022-01-21

Review 10.  Epidemiology of Systemic Mycoses in the COVID-19 Pandemic.

Authors:  María Guadalupe Frías-De-León; Rodolfo Pinto-Almazán; Rigoberto Hernández-Castro; Eduardo García-Salazar; Patricia Meza-Meneses; Carmen Rodríguez-Cerdeira; Roberto Arenas; Esther Conde-Cuevas; Gustavo Acosta-Altamirano; Erick Martínez-Herrera
Journal:  J Fungi (Basel)       Date:  2021-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.